News

Recordati Expands ISTURISA® Indication for Cushing’s Syndrome

Recordati Expands ISTURISA® Indication for Cushing’s Syndrome

Recordati Announces Expanded Approval of ISTURISA®

Recordati has made significant progress in the treatment of Cushing’s syndrome with the approval of ISTURISA® (osilodrostat) by the U.S. FDA. This expansion allows for the treatment of endogenous hypercortisolemia in adults who have not benefited from surgery or for whom surgery is not an option. This approval is expected to provide a new therapeutic avenue for patients suffering from this rare endocrine disorder.

Understanding Cushing’s Syndrome and ISTURISA®

Cushing's syndrome, characterized by excessively high cortisol levels, can profoundly affect patients and their families. ISTURISA® acts as a cortisol synthesis inhibitor, specifically targeting the enzyme 11?-hydroxylase, thus normalizing the heightened cortisol levels associated with the condition. This expanded indication not only offers hope to those affected but is also backed by an extensive clinical development program involving over 350 patients.

Impact of Cushing’s Syndrome on Patients

Cushing's syndrome can lead to severe complications such as diabetes, osteoporosis, cardiovascular diseases, and increased susceptibility to infections if left untreated. The medication ISTURISA® plays a crucial role in mitigating these effects, ensuring that patients can regain control over their health.

Scott Pescatore, Executive Vice President of Rare Diseases at Recordati, expressed his enthusiasm regarding this approval, emphasizing that the expanded label for ISTURISA® represents a critical advance in treating an unmet medical need. Elevated cortisol levels, if uncontrolled, pose significant health risks, and this approval will allow more patients to access effective treatment.

Clinical Significance of ISTURISA®

ISTURISA® offers a much-needed option for adult patients with endogenous hypercortisolemia and expands on the previous treatments limited to specific cases. This approval signifies a critical shift in the management of Cushing's syndrome, paving the way for enhanced treatment strategies.

Expert Opinions on Osilodrostat Expansion

Healthcare professionals, such as Dr. Maria Fleseriu, have noted that the expansion of the ISTURISA® indication is a pivotal development. It facilitates normalization of cortisol levels in patients unable to undergo surgery, thereby improving patient outcomes and quality of life.

Safety Information Regarding ISTURISA®

As with any medication, ISTURISA® comes with important safety information. It is crucial for patients to discuss their medical history with healthcare providers before starting treatment, especially concerning heart issues, electrolyte levels, and pregnancy status. Monitoring will be essential to mitigate potential side effects associated with treatment.

Common side effects may include low cortisol levels, fatigue, nausea, and swelling. It is vital for patients to report any adverse effects to their healthcare providers promptly, ensuring ongoing safety and efficacy of the treatment regimen.

About Recordati and ISTURISA®

Recordati is an esteemed international pharmaceutical group with a long-standing commitment to addressing health care challenges through innovative products. Their role in the treatment of rare diseases and specialty care is significant, with operations across numerous countries and a workforce dedicated to improving patient care.

ISTURISA® is already recognized in various international markets, securing its place as a valuable therapeutic option beyond U.S. borders. With commitments to continuous development and innovation, Recordati maintains its strategic focus on expanding access to vital medications for patients worldwide.

Frequently Asked Questions

What is ISTURISA® used for?

ISTURISA® is a prescription drug used to treat elevated cortisol levels in adults with Cushing’s syndrome who cannot have surgery or have not had success with surgical interventions.

How does ISTURISA® work?

ISTURISA® works by inhibiting the enzyme 11?-hydroxylase, which plays a crucial role in cortisol synthesis, thereby helping normalize cortisol levels in patients.

What are the possible side effects of ISTURISA®?

Possible side effects include low cortisol levels, fatigue, nausea, and swelling. Patients are advised to report any severe symptoms to their healthcare provider.

Is ISTURISA® safe for everyone?

ISTURISA® may not be safe for individuals with certain pre-existing conditions. Patients should consult their healthcare providers to assess individual risks before starting treatment.

Where is Recordati located?

Recordati is an international pharmaceutical group with its roots in Italy, operating in around 150 countries globally and focusing on specialty and rare diseases.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Holiday Grease Advice Shows Utility Work Up Close Today

Updated Category News Views 117

Butter and pan drippings are mundane right until they become a backed-up kitchen line on a crowded holiday afternoon. New Jersey American Water's Nov. 17, 2026 reminder is not glamorous utility news, and frankly it is not trying to be. It is a practical warning: fats, oils and grease can cool, harden and accumulate in household pipes and farther along the wastewater...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 101

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 58

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 113

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 75

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Yeahka Bids to Lead AI Shopping Evolution

Updated Category News Views 43

AI Shopping: A New Frontier or A Sisyphean Task? The evolution of AI from sassy recommendation tools to transaction-executing agents is shaking up the retail sector. Enter Stage Left: Yeahka Limited (9923.HK), a payment tech outfit that's wading into this murky digital swamp. With YeahPay and Fushi Tech, they're trying to hammer out a blueprint for AI-friendly commerce...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 124

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 107

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
Suntory Flowers Tests NASCAR as a Garden Retail Engine

Updated Category News Views 73

Orange sheet metal and flowering vines are an odd couple, which is precisely why this South Florida promotion has some bite. A plant marketer took a hard left turn Suntory Flowers put its Sun Parasol mandevillas alongside DGM Racing at Homestead-Miami Speedway, celebrating the millions of plants grown in South Florida. That is not a conventional horticulture play, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Coop Pank Reveals Q3 2025 Financial Results During Webinar

Updated Category News Views 161

Insights from Coop Pank's Recent Investor Webinar Coop Pank recently held an engaging investor webinar to discuss their unaudited financial results for the third quarter of 2025. During this informative session, Arko Kurtmann, the Chairman of the Management Board, and Paavo Truu, the Chief Financial Officer, elaborated on the bank's performance, highlighting significant...

Continue Reading
inTEST EMS Expands Market Reach Through New Distributor

Updated Category News Views 261

inTEST EMS Partners with General Bussan Co., Ltd. inTEST Electronic Test, part of inTEST Corporation (NYSE American: INTT), has announced a significant strategic partnership with General Bussan Co., Ltd. This collaboration is aimed at enhancing the distribution of inTEST EMS Products' high-quality manipulators, interface solutions, and docking systems designed...

Continue Reading
Gordon Brothers List Union Electric Steel Plant for Sale

Updated Category News Views 230

Gordon Brothers List Union Electric Steel Plant for Sale In the recent announcement, Gordon Brothers, renowned experts in asset management, are presenting a noteworthy opportunity for interested buyers. The entire roll manufacturing facility of Union Electric Steel Limited is now available for private sale, conducted by joint administrators. This facility is located in...

Continue Reading
AHLA Foundation's Summit Empowers Survivors and Experts

Updated Category News Views 157

Uniting Voices Against Human Trafficking The AHLA Foundation recently brought together a dynamic group of survivors, industry experts, and leaders at the No Room for Trafficking (NRFT) Summit. This significant event emphasized the importance of collaboration in the fight against human trafficking, focusing on education and the distribution of vital resources aimed at...

Continue Reading
Trump Media's Stock Reactions Amid Market Fluctuations Analysis

Updated Category News Views 158

Trump Media's Stock Takes a Hit Amid Insider Selling Concerns The shares of Trump Media have been quite turbulent lately, especially following reports that insiders within the company were given the green light to sell their holdings. This news is closely linked to former President Donald Trump, who has a significant stake in the company. Snapshot of Current Stock...

Continue Reading